Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study - Jules Higué; Corentin Orvain; Pierre-Yves Dumas; Pierre Peterlin; Marie-Anne Hospital; Sabrina Barrière; Audrey Couturier; Martin Carre; Areti Chantzi; Emmanuelle Tavernier; Éric Delabesse; Audrey Bidet; et al. (Blood Cancer Journal)